Part 1 - Briefly describe your internship by integrating your re.docx

Part 1 - Briefly describe your internship by integrating your
responses from the following questions: what type of
organization are you working for, what is the organization’s
mission/purpose, what is the department/unit/group where you
are interning and what does that department provide the
organization, and finally, what are you going to be responsible
for doing over the course of your internship.
What type of organization are you working for?
· I intern in body sculpting company
· Here’s their website
http://nutrientbodysculpt.com
What is the organization’s mission/purpose?
Can be found in the website under get to know Nutrient Body
Sculpt
What is the department/unit/group where you are interning and
what does that department provide the organization?
I intern in their Marketing department and they do all the
marketing for the company
Finally, what are you going to be responsible for doing over the
course of your internship?
My responsibilities are help with their social media, bring new
customers through social media and make campaign videos for
the company
Part 2 - Along with describing your organization/internship,
please identify 3 SMART Goals with the action steps you will
be taking to meet the goals/objectives you and your supervisor
agree that you need to be accomplishing over the course of your
internship. A hand-out will be provided for you on how to

complete SMART Goals and action steps
You NEED to identify 3 SMART goals
They must be specific
SMART GOAL SETTING & ACTION PLAN RESOURCE
SMART GOALS
A SMART Goal is a convenient acronym for the set of criteria
that a goal MUST include in order for it to be realized by the
goal achiever. There are numerous variations on the SMART
acronym, however. The one we will follow is:
Specific
Goals must be something that can be described and understood
easily by others - finite conditions, not general feelings.
Bad example: Increase participation of members.
Good example: increase attendance at chapter meetings.
Measurable
Whenever possible, use numbers or percentages to mark
achievement of the goal. You can't rely on personal opinion.
Bad example: More members will attend...
Good example: 80 percent of members will attend chapter

meetings.
Attainable
Is the goal realistic? Goals should be a stretch to obtain but not
impossible to achieve. Members will work toward what they
believe they can achieve and are not inspired by boring, easy
goals.
Bad example: 100 percent of members will attend every
meeting.
Good example: Increase attendance at chapter meetings by 10
percent from the prior semester.
Relevant
Your goals must accurately address the root issue you are
facing. Remember, "An accurate description of the problem, is
90 percent of the solution."
Bad example: Have alcohol at recruitment events so chapter
members will attend and have better conversations
Good example: Teach chapter members tangible recruitment
skills and eliminate alcohol from recruitment.
Timely
Goals must have an end date when they are due. Creating a
sense of urgency will push members to work harder. How else
will you know when to check performance?
Bad example: Winter
Good example: January 1, 2016
Examples
Non-SMART Goal: We need to improve recruitment
SMART Goal: By December 15, 2015, the chapter will have

recruited 20 new members who meet or exceed our minimum
membership standards.
ACTION PLANS
Every SMART goal must he complemented by a detailed action
plan. A good action plan provides the framework for achieving
the SMART goal The action plan helps map out the necessary
tasks with a detailed schedule of key milestones and a list of
key people for those milestones.
Overview
Great action plans:
• Determine what you will need to hit the goal.
• Provide a timetable for activities.
• Identify people with whom you will need to coordinate and
will rely on to contribute.
• Anticipate problems and outline contingency plans.
Implementation
For each of the three priorities identified on the Evaluation and
Prioritization Worksheet, follow this step-by step process to
ensure you have a comprehensive action plan:
1. Clarify your goal
-a Ensure it is specific, measureable, attainable, relevant and
timely.
2. Build a list of tasks
-a Write down all action steps that you may need to achieve the
goal.
3. Organize your fist into a plan
-a Decide on the order of action steps.
–b. Rearrange your actions and ideas into a sequential order.
-c. Review this list and see if there are any ways to simplify it
further.
Follow Up
1- Monitor the execution of your plan.
-a Constantly evaluate the progress of your plan.

-b. Manage the key people and be mindful of deadlines.
-c. Adjust and optimize your plan if necessary.
2. Measure your success.
-a Has your action plan achieved the outcomes of your SMART
goal?
Here are the 3 SMART goals I want you to state
1- Increase followers in Social Media
2- Make videos for our Marketing department
3- Order Bandages for the company and contact companies that
manufacture bandages especially from Chinese companies
EACH goal should focus on everything stated above
Each goal needs to be Specific, Measurable, Attainable,
Relevant, and Timely
And than begin with the Action plan for each goal
Table B. KQ2: Long-term (>1 year) effectiveness of
interventions for ADHD in people 6 years and
older
Conclusion
Medication Treatment
Level of EvidenceIntervention
SOE: Low Very few studies include untreated controls.

Studies were largely funded by industry.
SMD: -0.54 (95%
Cl, -0.79 to -0.29)
MPH:
Psychostimulants continue to provide control of ADHD
symptoms and are generally well tolerated for months to years
ATX: at a time. The evidence for MPH use in the context of
careful
SMD: -0.40 (95% medication monitoring shows good evidence
for benefits for
Cl, -0.61 to -0.18) symptoms for 14 months.
ATX is effective for ADHD symptoms and well tolerated over
12
months.
SOE: Insufficient Only one study of GXR monotherapy is
available. It reports
reduced ADHD symptoms and global improvement, although
less than a fifth of participants completed 12 months.
Monitoring of cardiac status may be indicated since
approximately 1% of participants showed EGG changes judged
clinically significant.
Combined The results from 2 cohorts indicate both medication
(MPH) and
Psychostimulant
SOE: Low
combined medication and behavioral treatment are effective in

Medication and SMD: -0.70 (95% treating ADHD plus ODD
symptoms in children, primarily boys
Behavioral ages 7-9 years of nomnal intelligence with combined
type of
Treatment
Cl, -0.95 to -0.46)
ADHD, especially during the first 2 years of treatment.
Several reports from one high-quality study suggest that
combined medication and behavioral treatment improves
outcomes more than medication alone for some subgroups of
children with ADHD combined type and for some outcomes.
Behavioral/ There is not enough evidence to draw conclusions
for persons
Psychosocial
SOE: Insufficient
6 years and older with a diagnosis of ADHD.
Parent Behavior There is not enough evidence to draw
conclusions for persons
Training
SOE: Insufficient
6 years and older with a diagnosis of ADHD.
Academic Interventions One good-quality study and its
extension showed that
classroom-based programs to enhance academic skills are
effective in improving achievement scores in multiple
domains, but following discontinuation, the benefits for
sustained growth in academic skills are limited to the domain
of reading fluency. All other domains show skill maintenance
but not continued growth.

SOE: Insufficient
..
Note: ADHD- attention defictt hyperactlvtty dtsorder, ATX-
atomoxetine, ECG- electrocardiOgram, GXR- guanfacme
extended release; KQ =Key Question; MPH= methylphenidate;
ODD= oppositional defiant disorder; SMD =standardized
mean difference; SOE =strength ofevidence.
ES-15
Pharmacological Interventions
Multiple short-term studies document that psycho stimulant
medications, either MPH,
dextroamphetamine (DEX), or mixed amphetamine salts (MAS),
effectively decrease the core
symptoms of ADHD and associated impairment. 10 A review of
the mechanisms of action of
pharmacological interventions for ADHD is beyond the scope of
this report. Some preparations
last only a few hours, with symptoms returning as the
medication wears off. Many families
choose to use medication primarily on school days, and these
medications have primarily been
studied in school-aged children and youth aged 6 years and
older. Psychostimulants, most
connnonly MPH and DEX, are generally safe and well tolerated.
Common side effects include
poor appetite, insomnia, headaches, stomachaches, and
increased blood pressure and heart rate.
Prolonged use may result in a decreased rate of growth,

generally considered clinically
insignificant.n8 Concerns have been raised from postmarketing
surveillance suggesting a rare
incidence of sudden death, perhaps associated with pre-existing
cardiac defects, however, the
rate does not appear to exceed that of the base rate of sudden
death in the population. 118 As noted
earlier, approximately 2.5 million children in the United States,
ages 4 to 17 years with a
diagnosis of Attention Deficit Disorder (ADD) or ADHD,
cunently take medication.4
Several extended release preparations of psychostimulants have
been developed in recent
years aimed at improved adherence and symptom control
throughout the day as well as
decreased abuse potential. 120 Non-stimulants (e.g., alpha
adrenergic agents and atomoxetine
(A TX)) have also been developed and found to be helpful in
controlling symptoms with few
adverse events. 121 However, in general, the benefits
ofmedications wear offwhen they are
discontinued. Since ADHD is a chronic disorder, many children,
teens, and adults stay on
medications for years at a time. Given the possibility of
cumulative effects over time, a review of
evidence regarding benefits and risks ofprolonged medication
use for ADHD is indicated.
Nonpharmacological Interventions
In the area of nonpharmacologic interventions, behavior
training has been found to be
helpful, primarily for disruptive behaviors that frequently
coincide with ADHD. 122 Since ADHD
may begin before school age, using the precedent of older

children, increasing numbers of
preschoolers are being identified and treated, sometimes with
medications. However, the most
commonly used psychostimulant, MPH, does not yet have
government regulatory approval for
use in children less than 6 years of age, while MAS has been
granted aEproval by the FDA in the
United States for children under 6 years, but older than 3 years
of age. 2 Recent reviews of
treatments for preschoolers with ADHD emphasize the use
ofparenting interventions prior to
medication based on general clinical consensus. 124 Indeed, the
Preschool ADHD Treatment
Study (PATS), funded by the U.S. National Institute for Mental
Health (NIMH), included parent
behavior training (PBT) as the first phase for all children
recruited into the study prior to
randomization for the purpose of evaluating efficacy and safety
ofpsychostimulant
medication.125 While the few studies available suggest
stimulant medications are effective for the
core symptoms of inattention, hyperactivity, and impulsiveness
in very young children,
psychostimulants also appear to cause more adverse events in
preschool children than in older
children.54 Beyond the PATS, little information exists to
document effectiveness of either
medication or non-medication interventions specifically for
ADHD in this age group. Part ofthe
difficulty has been lack of clarity regarding reliability and
validity of diagnostic criteria and
therefore lack ofwidespread application of the ADHD diagnosis
for children under 6 years.n 9
4

20161129102634348_000120161129102634348_0002
PATIENT FILE
151
PATIENT FILE
The Case: The scatter-brained mother whose daughter has
ADHD, like
mother, like daughter
The Question: How often does ADHD run in families?
The Dilemma: When you see a child with ADHD should you
also
evaluate the parents and siblings?
Pretest Self Assessment Question (answer at the end of the
case)
Patients with comorbid ADHD and anxiety should in general not
be
prescribed stimulants
A. True
B. False
Patient Intake
• 26-year-old woman
• Has a daughter with ADHD
• Psychiatrist noted symptoms in the mother and suggested she
come

in for her own evaluation
• See the previous Case 13, p 133 for presentation of the
daughter’s
case
Psychiatric History
• During interviews with the patient’s daughter (also attended
by the
patient) over the past several months, it was not only noted that
the
daughter has ADHD with comorbid ODD, but that the mother
also
exhibited multiple symptoms consistent with lifelong and
undiagnosed
ADHD including
– Mother misses appointments or is late for appointments
– Often appears disorganized
– Did not fi ll out her child’s forms on time
– Did not deliver forms to her child’s teacher, forgot, lost them
– Admits being very disorganized since her second child
started
school
– Feels overwhelmed by two children and her life
circumstances
– Could also have some signs of depression
– Can’t get organized to take her child to CBT
– Has a hard time keeping a regular schedule and also keeping
her
daughter on a regular schedule of going to bed and waking up
– Was unable to remember to remove the daughter’s skin patch

unless she set a cell phone alarm
– All these suggest further evaluation of the mother is
indicated
since ADHD commonly runs in families and has a very high
genetic contribution
Downloaded from http://stahlonline.cambridge.org
by IP 192.168.60.239 on Wed Jul 26 03:25:23 BST 2017
Stahl Online © 2017 Cambridge University Press.
All rights reserved. Not for commercial use or unauthorized
distribution.
PATIENT FILE
152
• Has always done poorly academically
• Has always felt intimidated by any type of testing
• In addition, reports that she has always been worried about the
future
and fi nancial stability of her family
• Says she sometimes mentally “freezes when it gets to be too
much”
• When her eight year old daughter was diagnosed with ADHD,
she
suddenly realized that she had similar problems as a child
• The psychiatrist explained to her that ADHD was highly
heritable and
that there was a 75% chance of having a child with ADHD if
both

parents have ADHD and thus was asked to fi ll out an Adult
ADHD
screening form
Social and Personal History
• High school drop out, age 17 after getting pregnant
• Married age 17, divorced 2 years later
• Two children, ages 8 and 6
• Smoker
• No drug or alcohol abuse
• Single mother works full time in retail
• Father not much involved with his children
Medical History
• None notable
• BP normal
• BMI normal
• Normal lab tests
Family History
• 8-year-old daughter: recently diagnosed with ADHD
• Other family history unknown as the patient was adopted
• See the previous Case 13, p 133 for presentation of the
daughter’s
case
Patient Intake
• The last time the patient brought her child to see the
psychiatrist, the
mother was asked to fi ll out her own checklist, the Adult
ADHD Self
Report Scale Symptom Checklist
– She endorsed many items, mostly inattentive but not really

hyperactive or impulsive such as:
– Having trouble wrapping up the fi nal details of a project
once
the challenging parts have been done
– Diffi culty getting things in order
– Diffi culty remembering appointments or obligations
distribution.
PATIENT FILE
153
– Making careless mistakes on diffi cult projects
– Diffi culty keeping attention on repetitive work
– Misplacing things at home and work
– Distracted by activity around her
– Diffi culty unwinding and relaxing when having time to
herself
– Diffi culty focusing/listening during conversations
• Earlier, the mother was also requested to obtain copies of her
report
cards from fi rst and second grade
– Her own mother had kept these in storage
– Showed grades that were quite low
– Her teachers had commented on some of the problems

endorsed
in the adult ADHD checklist that she continues to experience as
an
adult
• Asked how these problems affect her life, she states that:
– They cause great diffi culty managing family matters
– She used to be unable to stay focused in conversations with
her
ex-husband, which made him feel she did not care about him
• Additional complaints include:
– Constantly feeling overwhelmed with taking care of the two
children while working fulltime
– Blaming herself for her daughter’s academic diffi culties
– Feeling very emotional and overwhelmed
– “I’m sorry, doctor, but two kids are just too much for this
single
mom”
• Having diffi culty sleeping and being irritable with the
children at night,
which she regrets later on
• Has many worries, about fi nances, about the future, about her
children’s futures, about getting a better job, about getting her
own
education, about fi nding a new partner
Based on just what you have been told so far about this
patient’s history
and symptoms, what do you think is her diagnosis?

• Appropriate response to her circumstances with her severe
psychosocial stressors
• Mostly just stress and anxiety
• ADHD
• ADHD and stress
• Generalized anxiety disorder (GAD)
• Major depressive episode
• ADHD and GAD
• Other
distribution.
PATIENT FILE
154
Attending Physician’s Mental Notes: Initial Psychiatric
Evaluation
• Here is a case that indeed is ADHD, but her symptoms also
suggest
that she suffers from GAD
– Constant worry
– Feeling on edge
– Fatigue
– Diffi culty concentrating and her mind going blank
– Irritability
– Trouble sleeping

• Most adults with ADHD are comorbid for a second psychiatric
disorder, and the most common is GAD
• Also, this patient is a smoker which may be related to her
ADHD
since a disproportionate number of ADHD patients smoke,
perhaps
because of the therapeutic effects of nicotine on ADHD
symptoms
How would you treat her?
• Stimulant for her ADHD
• SSRI/SNRI for her GAD
• Benzodiazepine as need for GAD and insomnia
• Stimulant plus an SSRI/SNRI or benzo for both ADHD and
GAD
• CBT for both ADHD and GAD
• Other
Attending Physician’s Mental Notes, Initial Psychiatric
Evaluation, Continued
• It seems as though the primary disorder is ADHD and it will
be
simplest if this is treated fi rst, with a single drug, probably a
stimulant
• An SSRI/SNRI and/or benzodiazepine can be added at a later
time
once the actions of the stimulant are evident
• Even though patients with GAD alone or even normal controls
may be
“over stimulated” by a stimulant, in many cases of ADHD

comorbid
with GAD, the stimulant is paradoxically calming and well
tolerated
and even works for GAD symptoms as well as ADHD symptoms
without having to prescribe a second medication for the GAD
• Any stimulant could be chosen but not all are explicitly
approved for
treatment of ADHD in adults
• She was started on mixed salts d,l amphetamine XR (Adderall
XR)
• She was referred to a local mental health training program
where she
could possibly get CBT for free or for a reduced rate from a
trainee
receiving supervision
distribution.
PATIENT FILE
155
Case Outcome: First, Second, and Third Interim Followup
Visits, Weeks 4, 8 and 12
• Due to scheduling issues, by the time the patient had her fi rst
CBT

session, she had already been titrated to 20 mg of mixed salts of
d,l –
amphetamine XR
• She thought that the medication had already started to help her
and
in fact that she would not have been able to cooperate with the
CBT
assignments had she not been on the medication
• Because of lack of side effects but continuing ADHD and
GAD
symptoms, the dose of d,l-amphetamine XR increased to 30 mg
(off
label since the maximum approved dosage for adults is 20 mg)
• Her BP and pulse were stable on the 30 mg dose but she felt
jittery
particularly in the morning and around noon; she also felt very
anxious
about her job situation and being able to provide for her family
• Dose lowered to 25 mg, but the jitteriness persisted so the
dosage
was further lowerd to 20 mg
• The jitteriness abated but her ADHD symptoms were not well
controlled on the 20 mg dose anymore
• Instructed to stay on 20 mg for two more weeks as she is
going on
vacation and not to change the dose until after her vacation and
then
retry the 25 mg dose again
• Complained of feeling overwhelmed and irritable

• For most patients, a week between dosing adjustments for a
stimulant
being used to treat ADHD is quite adequate
• Weekly intervals give patients and clinicians a chance to see
the way
that the dosage is working though the spectrum of challenges
that
occur in a typical week
• As vacations do not represent typical activities for a week,
special
consideration must be given to the effectiveness of medication
changes that are done while a patient is on vacation
– Many adults with ADHD may relax on vacation and not
challenge
themselves with cognitive loads and multitasking so may appear
to be better even without a medication change
– Other adults with ADHD, especially women with young
children,
may actually fi nd vacation more challenging
– For example, a parent with ADHD taking a family vacation
with
several children in tow may fi nd the planning and organization
for
the trip more taxing than anything encountered at work or
during
the normal routine at home
– It can also be diffi cult to manage timing the medication
appropriately when traveling to different time zones

distribution.
PATIENT FILE
156
Case Outcome: Fourth Interim Followup, Week 16
• “Glad to be back from vacation”
• “I don’t think I could have even got through our vacation
without my
medication, but I still have a hard time holding things together”
• On at least 20 mg/day dosage of d,l-amphetamine XR
combined with
CBT for 12 weeks, including a couple of weeks back from
vacation,
the patient still has problems with
– Organizing her day
– Procrastinating
– Following instructions
– Losing items such as her keys which make her late for
appointments/activities
• On the few days that the patient missed, and thus skipped, her
medication inadvertently she realized that the medication was
really
helping her concentrate and get through the day even though she

remains symptomatic
• Knowing that she could achieve better functioning on
medication she
asked if other medications might accomplish this without the
jittery
and anxious feelings
• While other medication options were discussed, the CBT was
continued which was slightly less helpful
How would you treat her now?
• Start lisdexamfetamine 30 mg once in the morning and titrate
the
dosage by 20 mg each week until an optimal dosage is achieved
• Start d-methylphenidate XR 10 mg once in the morning and
titrate the
dosage by 10 mg each week until an optimal dosage is achieved
• Start OROS methylphenidate 18 mg once in the morning and
titrate
the dosage by 18 mg each week until an optimal dose is
achieved
• Start atomoxetine 40 mg a day and increase to 80 mg after one
week
Attending Physician’s Mental Notes: Fourth Interim Followup,
Week 16
• Lisdexamfetamine, d-methylphenidate XR, OROS
methylphenidate,
and atomoxetine are all FDA-approved for the treatment of
adults with

ADHD
• On the one hand, the patient found her amphetamine-based
stimulant
to be very effective, and thus another long-acting stimulant
would be
reasonable
• On the other hand, she had jitteriness with the stimulant, and
thus a
non-stimulant would be equally reasonable
• After explaining the options, the patient elected to try another
long-
acting stimulant
distribution.
PATIENT FILE
157
• d-methylphenidate uses a bead-based technology similar to the
mixed
salts amphetamine XR in that 50 percent of the beads are
immediate-
release and 50 percent delayed-released
• Methylphenidate LA and d-methylphenidate XR employ the
same

patented SODAS technology in their delivery systems, but other
long-
acting forms of stimulants with beaded delivery systems vary
due to
proprietary differences in their manufacturing processes
• For instance, one formulation of methylphenidate utilizes a
capsule
that contains a ratio of 30 percent immediate-release beads and
70
percent delayed-released beads
• Although the different technologies used in beaded forms of
stimulants can have clinical implications in individual cases,
they all
follow a similar design scheme:
– A bolus of stimulant medication becomes bioavailable rather
quickly as the immediate-release beads dissolve
– Over time, the coating on the delayed-release beads
deteriorates,
allowing the stimulant contained within the bead to be released
– The medication within the delayed-release bead becomes
bioavailable about four hours after the patient swallows the
capsule
• Lisdexamfetamine is the only stimulant preparation that is a
prodrug:
– In its prodrug form, a lysine molecule is attached to
dextroamphetamine
– Dextroamphetamine will not be active until the lysine is
cleaved

from it
– Cleaved lysine is an amino acid that does not contribute to
the
clinical effi cacy of this medication
• Lisdexamfetamine could be a good choice for multiple
reasons:
– It uses a different delivery system that appears to have a
more
consistent interval to maximum concentration (Cmax)
• It is conceivable that the jitteriness this patient was
experiencing was
related more to the l-isomer than to the d-isomer
• A nonstimulant such as atomoxetine may be particularly useful
in a
patient who has stimulant related side effects, because
atomoxetine
does not cause these side effects
• Also, atomoxetine may be particularly useful in patients with
comorbid anxiety
Case Outcome: Fourth Interim Followup, Week 16, Continued
• In the end, the patient and the attending physician agreed upon
a trial
of OROS methylphenidate (Concerta)
• Main reasons for this choice:
– To be able to compare the benefi ts the patient experienced
on
an amphetamine preparation with those of a methylphenidate

distribution.
PATIENT FILE
158
preparation since patients may experience differing
tolerabilities as
well as effi cacies on methylphenidate versus amphetamine
– To be able to test the uniqueness of the OROS delivery
system in
terms of attained effi cacy with better tolerability
• OROS methylphenidate uses a delivery system that is quite
different
from beaded delivery systems:
– Coating of OROS methylphenidate contains 32 percent of the
medication
– Remainder of medication is contained within a permeable
membrane that allows water from the gut to enter once the
coating
of methylphenidate dissolves away
– Different concentrations of methylphenidate in gel form are
contained in two compartments
– A push compartment absorbs water and expands like a sponge

does, pushing the methylphenidate gel out of the hole at the
opposite end
Case Outcome: Fifth Interim Followup, Week 20
• The patient’s dose was titrated from 18 mg to 72 mg over the
course
of four weeks
• Although she did not feel jittery, OROS methylphenidate 72
mg once a
day did not seem to work as well as the mixed salts
amphetamine at
30 mg a day
• She voiced concerns that the dosage was more than double that
of
the mixed salts amphetamine dosage that was tried
• The psychiatrist explained that methylphenidate compounds
are half
as potent as amphetamine ones, and that 72 mg/day is an
approved
dose in adults
• She was reminded that her blood pressure and pulse had
remained
in the normal range throughout the titration, and she was told
that
some of the methylphenidate gel may remain inside the delivery
system and not be bioavailable (inherent properties of OROS
technology)
• After documenting that information about off-label use was
given
to the patient, the psychiatrist recommended to further increase

the
dose of OROS methylphenidate to 90 mg
Case Outcome: Sixth Interim Followup, Week 24
• The patient felt that 90 mg of OROS methylphenidate worked
at least as
well as 30 mg of the mixed salts of d,l amphetamine XR
• Her blood pressure and pulse increased a bit from baseline,
but they
were still in the middle of the normal range
distribution.
PATIENT FILE
159
• She still has some problems with organization and losing
items, but
she indicates she would continue CBT to address these
• Similar to when she was on the amphetamine compound, once
her
ADHD symptoms abated, her anxious feelings became more
prominent
– “It’s like now that I can concentrate on my daily tasks, I also
feel

much more anxious about the fi nancial security of my children,
and I often feel my throat tighten when I think about the fi
nancial
impact of the girls going to college”
– “The thought of losing my job or getting sick frightens me . .
.
what would happen to the girls?”
– She has trouble falling asleep at night, as her mind does not
shut
off
ADHD is often comorbid with other psychiatric disorders and
one
disorder can mask the symptoms of another. In the present case,
this
patient exhibits symptoms of anxiety, probably generalized
anxiety
disorder, especially more prominent every time her ADHD
symptoms
abate. How would you address the patient’s anxiety at this
point?
• Augment with a benzodiazepine
• Augment with buspirone
• Augment with a selective serotonin reuptake inhibitor (SSRI)
or SNRI
• Incorporate techniques to resolve anxiety into ongoing CBT
Case Outcome: Seventh and Eighth Interim Followup, Weeks
24 and 36
• Incorporating techniques to resolve anxiety into the patient’s
ongoing
CBT would likely be most appropriate, prior to attempting to

add a
medication
• A letter was sent suggesting this to the CBT therapist, but
after 12
weeks, this led to limited benefi t, and thus medication
augmentation
was considered
• Benzodiazepines, buspirone, and SSRIs/SNRIs can all be used
to
treat generalized anxiety disorder and are not contraindicated
with
stimulants
• After discussion of the options, paroxetine was prescribed to
augment
her stimulant and her CTB
Case Outcome: Ninth Interim Followup, Week 48
• After three months on OROS methylphenidate and paroxetine,
while
continuing her CBT, at fi rst the patient stated that she “had her
life back”
• Then, after thinking back over the past year of treatment, and
to how
she had been since childhood she stated, “No, I don’t have my
life
back – I fi nally have a life!”

distribution.
PATIENT FILE
160
Case Debrief
• It took a long time to get both the ADHD and GAD recognized
• It took over a year of trial and error and combination
treatment to
attain a remission of symptoms
• Real remission will come when sustained improvement of
symptoms
leads to better functional outcomes, not only less subjective
distress,
but now perhaps the chance for an education, a better job, and
having
enough emotional reserve to develop another relationship
• Stopping smoking might be a goal to tackle in the next year as
well
Take-Home Points
• ADHD is highly heritable
• It is not uncommon for adults with previously undiagnosed
ADHD to
recognize their own symptoms once their child is diagnosed
• A multigenerational approach should be considered for parents
who
have ADHD and who care for children with ADHD

• In the patient’s case, by addressing her own ADHD issues, she
also
felt she could be a better parent to her daughter with ADHD
Performance in Practice: Confessions of a
Psychopharmacologist
• What could have been done better here?
– Perhaps ADHD could have been recognized earlier
– Perhaps CBT could have been implemented earlier
– Perhaps she should have been more actively engaged or have
had
more serious discussions about smoking cessation already
• Possible action item for improvement in practice
– Make a concerted effort to keep contact with low cost CBT
resources in the community
– Make a more concerted effort to encourage smoking cessation
Tips and Pearls
• Prescribing stimulants to an ADHD patient is very much like
tailoring a
“bespoke” treatment, one case at a time
• That is, some patients respond very differently to
amphetamine than
they do to methylphenidate
• Many patients respond very differently to one controlled
dosage
pattern versus another
• Look for comorbidities in adult ADHD, including both anxiety

disorders and substance dependence/abuse (especially smoking)
• True remission means reduction not just in symptoms of
ADHD, but
in the comorbid conditions as well
distribution.
PATIENT FILE
161
Two-Minute Tute: A brief lesson and psychopharmacology
tutorial (tute) with relevant background material for this case
– ADHD rating scales for adults
– Contributions of genetics to ADHD
Table 1: Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom
Checklist Instructions
distribution.
162

PATIENT FILE
distribution.
163
PATIENT FILE
distribution.
PATIENT FILE
164
Figure 1: Average Genetic Contribution of ADHD Based on
Twin Studies
ADHD is one of the most genetically loaded medical or
psychiatric
conditions, higher than schizophrenia, asthma or breast cancer.
Posttest Self Assessment Question: Answer

Patients with comorbid ADHD and anxiety should in general not
be
prescribed stimulants
A True
B False
Answer: B
References
1. Franke B, Neale BM, and Faraone SV. Genome-wide
association
studies in ADHD. Hum Genet 2009; 126(1): 13–50
2. Haberstick BC, Timberlake D, Hopfer CJ et al. Genetic and
environmental contributions to retrospectively reported DSM-IV
childhood attention defi cit hyperactivity disorder. Psychol Med
2008;
38(7): 1057–66
3. McLoughlin G, Ronald A, Kuntsi J et al. Genetic support for
the
dual nature of attention defi cit hyperactivity disorder:
substantial
genetic overlap between the inattentive and hyperactive-
impulsive
components. J Abnorm Child Psychol 2007; 35(6): 999–1008
4. Todd RD, Rasmussen ER, Neuman RJ et al. Familiality and
heritability of subtypes of attention defi cit hyperactivity
disorder in
a population sample of adolescent female twins. Am J
Psychiatry
2001; 158(11): 1891–8
5. Faraone SV, Advances in the genetics and neurobiology of

attention
defi cit hyperactivity disorder, Biol Psychiatry 2006; 60: 1025–
7
Twin studies: ADHD is genetic
Hudziak, 2000
Nadder, 1998
Levy, 1997
Sherman, 1997
Silberg, 1996
Gjone, 1996
Thapar, 1995
Schmitz, 1995
Edelbrock, 1992
Gillis, 1992
Goodman, 1989
Willerman, 1973
Breast cancer Asthma Schizophrenia Height
Average genetic contribution of ADHD based on twin studies
ADHD
mean
0 0.2 0.4 0.6 0.8 1

distribution.
PATIENT FILE
165
6. Stahl SM, Stahl’s Illustrated Attention Defi cit Hyperactivity
Disorder,
Cambridge University Press, New York, 2009
7. Stahl SM, Attention Defi cit Hyperactivity Disorder and its
Treatment,
in Stahl’s Essential Psychopharmacology, 3rd edition,
Cambridge
University Press, New York, 2008, pp 863–98
8. Stahl SM, Atomoxetine, in Stahl’s Essential
Psychopharmacology
The Prescriber’s Guide, 3rd edition, Cambridge University
Press,
New York, 2009, pp 51–5
9. Stahl SM, d,l methylphenidate, in Stahl’s Essential
Psychopharmacology The Prescriber’s Guide, 3rd edition,
Cambridge University Press, New York, 2009, pp 329–35
10. Stahl SM, Mixed Salts of d,l Amphetamine, in Stahl’s
Essential
Psychopharmacology The Prescriber’s Guide, 3rd edition,
Cambridge University Press, New York, 2009, pp 39–44
11. Stahl SM, Paroxetine, in Stahl’s Essential
Psychopharmacology The

Prescriber’s Guide, 3rd edition, Cambridge University Press,
New
York, 2009, pp 409–15
distribution.

Part 1 - Briefly describe your internship by integrating your re.docx

Recommended

Recommended

More Related Content

Similar to Part 1 - Briefly describe your internship by integrating your re.docx

Similar to Part 1 - Briefly describe your internship by integrating your re.docx (19)

More from danhaley45372

More from danhaley45372 (20)

Recently uploaded

Recently uploaded (20)

Part 1 - Briefly describe your internship by integrating your re.docx